000279492 001__ 279492
000279492 005__ 20250709100939.0
000279492 037__ $$aDZNE-2025-00819
000279492 1001_ $$0P:(DE-2719)2810938$$aMüller, Stephan A$$b0$$udzne
000279492 245__ $$aDataset: Plasma proteomics of BACE1, 2, and double KO mice
000279492 260__ $$bPRoteomics IDEntifications Database$$c2024
000279492 3367_ $$2BibTeX$$aMISC
000279492 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1752047314_8073
000279492 3367_ $$026$$2EndNote$$aChart or Table
000279492 3367_ $$2DataCite$$aDataset
000279492 3367_ $$2ORCID$$aDATA_SET
000279492 3367_ $$2DINI$$aResearchData
000279492 520__ $$aThe beta-secretase BACE1 is a central drug target for Alzheimer’s disease. Clinically tested, BACE1-directed inhibitors also block the homologous protease BACE2. Yet, little is known about physiological BACE2 substrates and functions in vivo. Here, we performed glycoprotein enrichment and subsequent discovery proteomics to identify substrates of the protease BACE2 in plasma of mice. Therefore, we analysed plasma from BACE2 KO, BACE1/2 double KO and WT controls, as well as BACE1 KO with a separate WT control. Inactivation of BACE2, but not BACE1, inhibited shedding of VEGFR3/FLT4. Thus, sVEGFR3 represents a pharmacodynamic plasma marker for BACE2 activity in vivo.
000279492 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000279492 7001_ $$0P:(DE-2719)2181459$$aLichtenthaler, Stefan$$b1$$udzne
000279492 7870_ $$0DZNE-2024-01041$$aSchmidt, Andree et.al.$$dAnn Arbor, Mich. : ASCJ, 2024$$iRelatedTo$$r$$tThe Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling.
000279492 8564_ $$uhttps://wwwdev.ebi.ac.uk/pride/archive/projects/PXD041577
000279492 909CO $$ooai:pub.dzne.de:279492$$pVDB
000279492 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810938$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000279492 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2181459$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000279492 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000279492 9201_ $$0I:(DE-2719)1110006$$kAG Lichtenthaler$$lNeuroproteomics$$x0
000279492 980__ $$adataset
000279492 980__ $$aVDB
000279492 980__ $$aI:(DE-2719)1110006
000279492 980__ $$aUNRESTRICTED